| Jun 24 |
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
|
| Jun 20 |
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Jun 14 |
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
|
| Jun 13 |
Is Castle Biosciences (CSTL) Outperforming Other Medical Stocks This Year?
|
| May 30 |
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
|
| May 29 |
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
|
| May 23 |
Does Castle Biosciences (CSTL) Have the Potential to Rally 36.15% as Wall Street Analysts Expect?
|
| May 23 |
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
|
| May 15 |
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
|
| May 14 |
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
|
